IN THE CLAIMS:

Please amend the claims as follows:

Claim 1 **(original)**: A compound of the formula **(IA), (IB), (IC), (ID), (IE)** and **(IF)** of the generic structure of formula **(I)**:



(I)

wherein:

i) a compound of formula **(IA)** is selected from:



(IA)

wherein:

R^1 is 2-(pyrazolyl-1-yl)ethyl, 3-(isoxazol-3-yloxy)propyl, 2-(isothiazol-3-yloxy)ethyl, 2-(thiadiazol-3-yloxy)ethyl, 1,3-dihydroxyprop-2-yl, 1-methyl-1-hydroxymethylethyl, 1,1-dimethylpropyl, 1-methylcyclopropyl, *t*-butyl, 2-morpholino-1,1-dimethylethyl, 2-pyrrolidin-1-yl-1,1-dimethylethyl, 2-methylthio-1,1-dimethylethyl, 1,3-dimethoxyprop-2-yl,

1-methoxyprop-2-yl, 1-hydroxyprop-2-yl, 1-ethoxyprop-2-yl, 1-propoxyprop-2-yl, ethoxyethyl or 2-methoxy-1,1-dimethylethyl; and

R^2 is hydrogen;

or R^1 and R^2 together form 2,2-dimethylaziridin-1-yl;

or a pharmaceutically acceptable salt or an *in vivo* hydrolysable ester thereof;

ii) a compound of formula **(IB)** is selected from:



(IB)

wherein:

R^1 is pyrid-2-ylmethyl, 2-(2-methyl-1,2,4-triazol-5-yl)ethyl, 2-pyrid-2-ylethyl, 2-pyridazin-3-ylethyl, 2-(3,5-dimethyltriazol-4-yl)ethyl, 2-pyrid-3-ylethyl, 2-methoxyethyl, 3-(5-methylpyrazol4-yl)propyl, 2-trifluoromethylpyrid-5-ylmethyl, 2-pyridazin-4-ylethyl, 1,1-dimethylprop-2-ynyl, 2-ethoxyethyl, 2-phenoxyethyl, 2-(4-methoxyphenoxy)ethyl, 2-(2-methoxyphenoxy)ethyl, 2-(vinyloxy)ethyl, 2-(isopropoxy)ethyl and 2-(propoxy)ethyl; and

R^2 is hydrogen or cyano;

or a pharmaceutically acceptable salt or an *in vivo* hydrolysable ester thereof;

provided that when R^1 is 2-methoxyethyl, R^2 is cyano;

iii) a compound of formula **(IC)** is selected from:



(IC)

wherein:

R^1 is hydrogen, heterocyclyl, C_{1-6}alkyl or C_{1-6}alkoxyC_{1-6}alkyl; wherein R^1 may be optionally substituted on carbon by one or more hydroxy, carboxy, C_{1-6}alkoxy, C_{1-6}alkoxycarbonyl, *N,N*-(C_{1-6}alkyl)$_2$amino, heterocyclyl, C_{3-6}cycloalkyl and C_{1-6}alkoxyC_{1-6}alkoxy; and wherein if a heterocyclyl contains an -NH- moiety, that nitrogen may be optionally substituted by C_{1-6}alkyl or benzyl;

R^2 is hydrogen, halo or cyano;

or a pharmaceutically acceptable salt or an *in vivo* hydrolysable ester thereof;

provided that when R^1 is 2-methoxyethyl, cyclopropylmethyl or pyrid-2-ylmethyl, R^2 is not hydrogen;

iv) a compound of formula **(ID)** is selected from:



(ID)

wherein:

R^1 is hydrogen, C_{1-4}alkyl, C_{2-4}alkenyl, C_{2-4}alkynyl, C_{3-6}cycloalkyl, C_{3-6}cycloalkylC_{1-3}alkyl, a heterocyclyl or heterocyclylC_{1-3}alkyl; wherein R^1 may be optionally substituted on carbon by one or more methyl, ethyl, methoxy, ethoxy, propoxy,

trifluoromethyl, trifluoromethoxy, 2,2,2-trifluoroethoxy or cyclopropylmethoxy; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by one or more methyl, ethyl, acetyl, 2,2,2-trifluoroethyl or methoxyethyl;

$\mathbf{R^2}$ is hydrogen, halo or cyano;

$\mathbf{R^3}$ is C_{2-6}alkyl;

or a pharmaceutically acceptable salt or an *in vivo* hydrolysable ester thereof;

v) a compound of formula **(IE)** is selected from:



(IE)

wherein:

$\mathbf{R^1}$ is hydrogen, C_{1-4}alkyl, C_{2-4}alkenyl, C_{2-4}alkynyl, C_{3-6}cycloalkyl, C_{3-6}cycloalkylC_{1-3}alkyl, a heterocyclyl or heterocyclylC_{1-3}alkyl; wherein R^1 may be optionally substituted on carbon by one or more methyl, ethyl, methoxy, ethoxy, propoxy, trifluoromethyl, trifluoromethoxy, 2,2,2-trifluoroethoxy or cyclopropylmethoxy; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by one or more methyl, ethyl, acetyl, 2,2,2-trifluoroethyl or methoxyethyl;

$\mathbf{R^2}$ is halo, cyano, C_{1-3}alkyl or C_{1-3}alkoxy;

p is 1-2; wherein the values of R^2 may be the same or different;

$\mathbf{R^3}$ is hydrogen, halo or cyano;

$\mathbf{R^4}$ is C_{1-4}alkyl;

$\mathbf{R^5}$ is C_{1-6}alkyl or C_{2-6}alkenyl; wherein R^5 may be optionally substituted on carbon by one or more methoxy, ethoxy, propoxy, trifluoromethyl, trifluoromethoxy, 2,2,2-trifluoroethoxy or cyclopropylmethoxy;

or a pharmaceutically acceptable salt or an *in vivo* hydrolysable ester thereof;

provided that said compound is not

4-(1,2-dimethylimidazol-5-yl)-2-[2-methoxy-4-(*N*-methylsulphamoyl)-5-methylanilino]pyrimidine;

vi) a compound of formula **(IF)** is selected from:



(IF)

wherein:

R^1 is C_{1-4}alkyl, C_{2-4}alkenyl, C_{2-4}alkynyl, C_{3-6}cycloalkyl, C_{3-6}cycloalkylC_{1-3}alkyl, a heterocyclyl or heterocyclylC_{1-3}alkyl; wherein R^1 may be optionally substituted on carbon by one or more methyl, ethyl, methoxy, ethoxy, propoxy, trifluoromethyl, trifluoromethoxy, dimethylamino, 2,2,2-trifluoroethoxy, phenyl or cyclopropylmethoxy; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by one or more methyl, ethyl, acetyl, 2,2,2-trifluoroethyl or methoxyethyl;

R^2 is halo, cyano, C_{1-3}alkyl or C_{1-3}alkoxy;

p is 0-2; wherein the values of R^2 may be the same or different;

R^3 is hydrogen, halo or cyano;

R^4 is C_{2-6}alkyl;

R^5 is C_{1-6}alkyl or C_{2-6}alkenyl; wherein R^5 may be optionally substituted on carbon by one or more methoxy, ethoxy, propoxy, trifluoromethyl, trifluoromethoxy, 2,2,2-trifluoroethoxy or cyclopropylmethoxy;

or a pharmaceutically acceptable salt or an *in vivo* hydrolysable ester thereof;

vii) a compound of formula **(IG)** is selected from:



(IG)

wherein:

R^1 is C_{1-4}alkyl, C_{2-4}alkenyl, C_{2-4}alkynyl, C_{3-6}cycloalkyl, C_{3-6}cycloalkylC_{1-3}alkyl, a heterocyclyl or heterocyclylC_{1-3}alkyl; wherein R^1 may be optionally substituted on carbon by one or more methyl, ethyl, methoxy, ethoxy, propoxy, trifluoromethyl, trifluoromethoxy, dimethylamino, 2,2,2-trifluoroethoxy, phenyl or cyclopropylmethoxy; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by one or more methyl, ethyl, acetyl, 2,2,2-trifluoroethyl or methoxyethyl;

R^2 is halo, cyano, C_{1-3}alkyl or C_{1-3}alkoxy;

p is 0-2; wherein the values of R^2 may be the same or different;

R^3 is hydrogen, halo or cyano;

R^4 is n-propyl or C_{4-6}alkyl;

or a pharmaceutically acceptable salt or an *in vivo* hydrolysable ester thereof.

Claim 2 **(original)**: A compound of formula **(I)** according to claim 1 which is a compound of formula **(IA)**, or a pharmaceutically acceptable salt or an *in vivo* hydrolysable ester thereof.

Claim 3 **(original)**: A compound of formula **(IA)** selected from:

2-{4-[*N*-(2-ethoxyethyl)sulphamoyl]anilino}-4-(1,2-dimethylimidazol-5-yl)pyrimidine;

2-{4-[*N*-(*t*-butyl)sulphamoyl]anilino}-4-(1,2-dimethylimidazol-5-yl)pyrimidine;

2-{4-[*N*-(1-ethoxyprop-2-yl)sulphamoyl]anilino}-4-(1,2-dimethylimidazol-5-yl)pyrimidine;

2-{4-[*N*-(1-propoxyprop-2-yl)sulphamoyl]anilino}-4-(1,2-dimethylimidazol-5-yl)pyrimidine; and
2-{4-[*N*-(1-methylcyclopropyl)sulphamoyl]anilino}-4-(1,2-dimethylimidazol-5-yl)pyrimidine; or a pharmaceutically acceptable salt or an *in vivo* hydrolysable ester thereof.

Claim 4 **(original)**: A compound of formula **(I)** according to claim 1 which is a compound of formula **(IB)**, or a pharmaceutically acceptable salt or an *in vivo* hydrolysable ester thereof.

Claim 5 **(original)**: A compound of formula **(IB)** selected from:
4-(1-ethyl-2-methylimidazol-5-yl)-2-{4-[*N*-(2-ethoxyethyl)sulphamoyl]anilino}pyrimidine;
2-{4-[*N*-(2-isopropoxyethyl)sulphamoyl]anilino}-4-(1-ethyl-2-methylimidazol-5-yl)pyrimidine;
2-{4-[*N*-(2-propoxyethyl)sulphamoyl]anilino}-4-(1-ethyl-2-methylimidazol-5-yl)pyrimidine;
2-{4-[*N*-(1,1-dimethylprop-2-ynyl)sulphamoyl]anilino}-4-(1-ethyl-2-methylimidazol-5-yl)pyrimidine; and
2-{4-[*N*-(2-vinyloxyethyl)sulphamoyl]anilino}-4-(1-ethyl-2-methylimidazol-5-yl)pyrimidine; or a pharmaceutically acceptable salt or an *in vivo* hydrolysable ester thereof.

Claim 6 **(original)**: A compound of formula **(I)** according to claim 1 which is a compound of formula **(IC)**, or a pharmaceutically acceptable salt or an *in vivo* hydrolysable ester thereof.

Claim 7 **(original)**: A compound of formula **(IC)** according to claim 6, or a pharmaceutically acceptable salt or an *in vivo* hydrolysable ester thereof; wherein

R^1 is hydrogen, 2-methoxyethyl, methyl, 2-ethoxyethyl, 2-isopropoxyethyl, 2-propoxyethyl, 2-(cyclopropylmethoxy)ethyl, 3-(*t*-butoxy)propyl, 3-[2-(2-ethoxyethoxy)ethoxy]propyl, 3-(2-methoxyethoxy)propyl, carboxymethyl, *t*-butoxycarbonylmethyl, 2-hydroxyethyl, 2-(*N*-methylpyrrolidin-2-yl)ethyl,

N-ethylpyrrolidin-2-ylmethyl, 2-pyrrolidin-1-ylethyl, 2-morpholinoethyl, 3-morpholinopropyl, *N*-benzylpiperidin-4-yl, 2-piperdin-1-ylethyl, 2-dimethylaminoethyl, 2-diethylaminoethyl or methoxycarbonylmethyl; and

R^2 is hydrogen or bromo;

provided that when R^1 is 2-methoxyethyl R^2 is not hydrogen.

Claim 8 **(original)**: A compound of formula **(IC)** selected from:
4-(1-isopropyl-2-methylimidazol-5-yl)-2-{4-[*N*-(2-ethoxyethyl)sulphamoyl]anilino} pyrimidine;
4-(1-isopropyl-2-methylimidazol-5-yl)-2-{4-[*N*-(2-isopropoxyethyl)sulphamoyl]anilino} pyrimidine;
4-(1-isopropyl-2-methylimidazol-5-yl)-2-{4-[*N*-(2-propoxyethyl)sulphamoyl]anilino} pyrimidine;
4-(1-isopropyl-2-methylimidazol-5-yl)-2-(4-{*N*-[2-(cyclopropylmethoxy)ethyl]sulphamoyl} anilino)pyrimidine; and
4-(1-isopropyl-2-methylimidazol-5-yl)-2-{4-[*N*-(methyl)sulphamoyl]anilino} pyrimidine;
or a pharmaceutically acceptable salt or an *in vivo* hydrolysable ester thereof.

Claim 9 **(original)**: A compound of formula **(I)** according to claim 1 which is a compound of formula **(ID)**, or a pharmaceutically acceptable salt or an *in vivo* hydrolysable ester thereof.

Claim 10 **(original)**: A compound of formula **(ID)** according to claim 9, or a pharmaceutically acceptable salt or an *in vivo* hydrolysable ester thereof; wherein

R^1 is cyclopropyl, 2-methoxyethyl, 2-ethoxyethyl or tetrahydrofur-2-ylmethyl;

R^2 is hydrogen; and

R^3 is ethyl, propyl or isopropyl.

Claim 11 **(original)**: A compound of formula **(ID)** selected from:

4-(1-isopropylimidazol-5-yl)-2-{4-[*N*-(cyclopropyl)sulphamoyl]anilino}pyrimidine;
4-(1-isopropylimidazol-5-yl)-2-{4-[*N*-(tetrahydrofur-2-ylmethyl)sulphamoyl]anilino}
pyrimidine;
4-(1-propylimidazol-5-yl)-2-{4-[*N*-(2-methoxyethyl)sulphamoyl]anilino}pyrimidine;
4-(1-ethylimidazol-5-yl)-2-{4-[*N*-(2-methoxyethyl)sulphamoyl]anilino}pyrimidine; and
4-(1-isopropylimidazol-5-yl)-2-{4-[*N*-(2-methoxyethyl)sulphamoyl]anilino}pyrimidine;
or a pharmaceutically acceptable salt or an *in vivo* hydrolysable ester thereof.

Claim 12 **(original)**: A compound of formula **(I)** according to claim 1 which is a compound of formula **(IE)**, or a pharmaceutically acceptable salt or an *in vivo* hydrolysable ester thereof.

Claim 13 **(original)**: A compound of formula **(IE)** according to claim 12, or a pharmaceutically acceptable salt or an *in vivo* hydrolysable ester thereof; wherein

R^1 is hydrogen or 2-methoxyethyl;

R^2 is fluoro;

p is 1;

R^3 is hydrogen; and

R^4 is methyl.

Claim 14 **(original)**: A compound of formula **(IE)** selected from:
2-{4-[*N*-(2-methoxyethyl)sulphamoyl]-2-fluoroanilino}-4-(1,2-dimethylimidazol-5-yl)pyrimidine; and
2-(4-sulphamoyl-2-fluoroanilino)-4-(1,2-dimethylimidazol-5-yl)pyrimidine;
or a pharmaceutically acceptable salt or an *in vivo* hydrolysable ester thereof.

Claim 15 **(original)**: A compound of formula **(I)** according to claim 1 which is a compound of formula **(IF)**, or a pharmaceutically acceptable salt or an *in vivo* hydrolysable ester thereof.

Claim 16 **(original)**: A compound of formula **(IF)** according to claim 15, or a pharmaceutically acceptable salt or an *in vivo* hydrolysable ester thereof; wherein

R^1 is methyl, 3-dimethylaminopropyl, 3-methoxypropyl, 3,3,3-trifluoropropyl, butyl, benzyl, tetrahydrofur-2-ylmethyl, 3-ethoxypropyl or 3-morpholinopropyl;

p is 0;

R^3 is hydrogen or bromo;

R^4 is isopropyl; and

R^5 is methyl.

Claim 17 **(original)**: A compound of formula **(IF)** selected from:
4-(1-isopropyl-2-methylimidazol-5-yl)-2-(4-mesylanilino)pyrimidine;
4-(1-isopropyl-2-methylimidazol-5-yl)-2-[4-(tetrahydrofur-2-ylmethylsulphonyl)anilino] pyrimidine;
4-(1-isopropyl-2-methylimidazol-5-yl)-2-[4-(3-ethoxypropylsulphonyl)anilino]pyrimidine;
4-(1-isopropyl-2-methylimidazol-5-yl)-2-[4-(3-methoxypropylsulphonyl)anilino]pyrimidine; and
4-(1-isopropyl-2-methylimidazol-5-yl)-2-[4-(3-*N,N*-dimethylaminopropylsulphonyl)anilino] pyrimidine;
or a pharmaceutically acceptable salt or an *in vivo* hydrolysable ester thereof.

Claim 18 **(original)**: A compound of formula **(I)** according to claim 1 which is a compound of formula **(IG)**, or a pharmaceutically acceptable salt or an *in vivo* hydrolysable ester thereof.

Claim 19 **(original)**: A compound of formula **(IG)** according to claim 18, or a pharmaceutically acceptable salt or an *in vivo* hydrolysable ester thereof; wherein

R^1 is 2-methoxyethyl, 2-ethoxyethyl or cyclopropyl;

p is 0;

R^3 is hydrogen; and

R^4 is n-propyl or isobutyl.

Claim 20 **(original)**: A compound of formula **(IG)** selected from:
4-(1-propyl-2-methylimidazol-5-yl)-2-{4-[*N*-(2-ethoxyethyl)sulphamoyl]anilino}pyrimidine;
4-(1-propyl-2-methylimidazol-5-yl)-2-{4-[*N*-(2-methoxyethyl)sulphamoyl]anilino}
pyrimidine;
4-(1-propyl-2-methylimidazol-5-yl)-2-{4-[*N*-(cyclopropyl)sulphamoyl]anilino}pyrimidine;
4-(1-isobutyl-2-methylimidazol-5-yl)-2-{4-[*N*-(2-methoxyethyl)sulphamoyl]anilino}
pyrimidine; and
4-(1-isobutyl-2-methylimidazol-5-yl)-2-{4-[*N*-(2-
ethoxyethyl)sulphamoyl]anilino}pyrimidine;
or a pharmaceutically acceptable salt or an *in vivo* hydrolysable ester thereof.

Claim 21 **(original)**: A pharmaceutical composition which comprises a compound of formula **(I)**, or a pharmaceutically acceptable salt or *in vivo* hydrolysable ester thereof, according to any one of claims 1-20, in association with a pharmaceutically-acceptable diluent or carrier.

Claims 22-32 **(cancelled).**

Claim 33 **(new)**: A method for producing a cell cycle inhibitory (anti-cell-proliferation) effect in a warm-blooded animal in need thereof, which comprises administering to said animal an effective amount of a compound of formula **(I)** or a pharmaceutically acceptable salt or *in vivo* hydrolysable ester thereof as claimed in claim 1.

Claim 34 **(new)**: A method for the inhibition of CDK2, CDK4 or CDK6 in a warm-blooded animal in need thereof, which comprises administering to said animal an

effective amount of a compound of formula **(I)** or a pharmaceutically acceptable salt or *in vivo* hydrolysable ester thereof as claimed in claim 1.

Claim 35 **(new)**: A method for treating a disease or medical condition selected from cancer (solid tumours and leukaemias), fibroproliferative and differentiative disorders, psoriasis, rheumatoid arthritis, Kaposi's sarcoma, haemangioma, acute and chronic nephropathies, atheroma, atherosclerosis, arterial restenosis, autoimmune diseases, acute and chronic inflammation, bone diseases and ocular diseases with retinal vessel proliferation, in a warm-blooded animal in need thereof, which comprises administering to said animal an effective amount of a compound of formula **(I)** or a pharmaceutically acceptable salt or *in vivo* hydrolysable ester thereof as claimed in claim 1.

Claim 36 **(new)**: A method of treating cancer in a warm-blooded animal in need thereof, which comprises administering to said animal an effective amount of a compound of formula **(I)** or a pharmaceutically acceptable salt or in vivo hydrolysable ester thereof as claimed in claim 1.

Claim 37 **(new)**: The method of claim 36 wherein said cancer is selected from leukaemia, breast cancer, lung cancer, colorectal cancer, stomach cancer, prostate cancer, bladder cancer, pancreatic cancer, ovarian cancer, liver cancer, kidney cancer, skin cancer and cancer of the vulva.

Claim 38 **(new)**: A method for preventing hair loss arising from the treatment of malignant conditions with pharmaceutical agents in a warm-blooded animal in need thereof, which comprises administering to said animal an effective amount of a compound of formula **(I)** or a pharmaceutically acceptable salt or in vivo hydrolysable ester thereof as claimed in claim 1.